676476-90-7

Usage

Uses

Used in Organic Synthesis:
2,2,2-trifluoro-1-(6-nitro-1H-indol-3-yl)ethan-1-one is used as a synthetic intermediate for the preparation of complex molecules in organic chemistry. Its trifluoromethyl ketone functional group facilitates the introduction of fluorine atoms, which can enhance the stability and reactivity of the resulting compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2,2,2-trifluoro-1-(6-nitro-1H-indol-3-yl)ethan-1-one is employed as a building block for the synthesis of pharmaceuticals and biologically active compounds. The presence of the nitro group and the indole moiety allows for the development of molecules with targeted biological and pharmacological properties, making it a versatile component in drug design.
Used in Pharmaceutical Industry:
2,2,2-trifluoro-1-(6-nitro-1H-indol-3-yl)ethan-1-one is used as a key component in the development of new drugs. Its unique structure and functional groups enable the creation of molecules with improved therapeutic effects and reduced side effects, contributing to the advancement of pharmaceutical research and development.
Used in Biological Research:
2,2,2-trifluoro-1-(6-nitro-1H-indol-3-yl)ethan-1-one is utilized in biological research as a tool to study the effects of fluorination and the incorporation of specific functional groups on the biological activity of molecules. This can lead to a better understanding of molecular interactions and the development of more effective therapeutic agents.

Upstream product

• 4769-96-4 6-nitroindole 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 10242-03-2 6-nitro-1H-indole-3-carboxylic acid 
• 934231-65-9 1-(1-benzyl-6-nitro-1H-indole-3-yl)-2,2,2-trifluoroethanone 

Relevant academic research and scientific papers

Synthesis of a Series of Diaminoindoles

A selection of 3,4-diaminoindoles were required for a recent drug discovery project. To this end, a 10-step synthesis was developed from 4-nitroindole. This synthesis was subsequently adapted and used to synthesize 3,5-; 3,6-; and 3,7-diaminoindoles from

NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS

The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1 ), and their use as pharmaceutical compositions.

NOVEL FUSED PYRROLE DERIVATIVE

Disclosed is a compound represented by the formula (1) below which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory drug or an antidiabetic drug, or a pharmaceutically acceptable salt thereof. (1) [In the formula, R1 represents an aralkyl group or the like; R2 represents a hydrogen atom or the like; -W4=W5-W6=W7- represents a group expressed as the following formula: -CR4=CR5-CR6=CR7- (wherein R4, R5, R6 and R7 independently represent a group expressed as the following formula: -E-A (wherein E represents a single bond and A represents a hydrogen atom, a nitro group or the like)) or the like; R8 represents a group expressed as the following formula: -OR11 (wherein R11 represents a hydrogen atom or the like) or the like; R9 represents a trifluoromethyl group or the like; and R10 represents a group expressed as the following formula: -[C(R13)R14]n-R15 (wherein R13 and R14 independently represent a hydrogen atom or the like, n represents an integer of 0-10, and R15 represents a group expressed as the following formula: -N(R18)R19 (wherein R18 and R19 represent a monocyclic nitrogen-containing heterocyclic ring or the like together with a nitrogen atom to which they are bonded) or the like).]

Indole-3-carboxamides as glucokinase activators

The present invention provides glucokinase activators of formula I: wherein R1, R2 and R3 are defined in the specification. Glucokinase activators are useful for increasing insulin secretion in the treatment of type II diabetes.